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Musashi-2 (MSI2) belongs to Musashi family of RNA binding proteins (RBP). Like
Musashi-1 (MSI1), it is overexpressed in a variety of cancers and is a promising thera-
peutic target. Both MSI proteins contain two N-terminal RNA recognition motifs and
play roles in posttranscriptional regulation of target mRNAs. Previously, we have
identified several inhibitors of MSI1, all of which bind to MSI2 as well. In order to
design MSI2-specific inhibitors and compare the differences of binding mode of the
inhibitors, we set out to solve the structure of MSI2-RRM1, the key motif that is
responsible for the binding. Here, we report the crystal structure and the first NMR
solution structure of MSI2-RRM1, and compare these to the structures of
MSI1-RBD1 and other RBPs. A high degree of structural similarity was observed
between the crystal and solution NMR structures. MSI2-RRM1 shows a highly similar
overall folding topology to MSI1-RBD1 and other RBPs. The structural information
of MSI2-RRM1 will be helpful for understanding MSI2-RNA interaction and for guid-
ing rational drug design of MSI2-specific inhibitors.
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1 | INTRODUCTION
The RNA-binding protein (RBP) Musashi-2 (MSI2) is overexpressed in
many cancers, including colorectal adenocarcinomas,1-3 breast,4,5
hematologic malignancies,6-12 lung,13 glioblastoma,14 and pancreatic
cancers.15-17 As such, it mediates mRNA stability and translation of
proteins involved in oncogenic pathways.18-20 Overexpression and
knockdown studies indicate that MSI2 is a promising therapeutic tar-
get for cancer.3,13,16,21,22
Human MSI2 is a 328 amino acid protein that contains two RNA
recognition motifs (RRMs) spanning G21-K111 (RRM1) and
K110-P187 (RRM2). A BLAST23 search revealed that MSI2 (residues
F IGURE 1 Clustal multiple sequence alignment of human MSI2, human MSI1, and mouse MSI1. Identical residues are highlighted in green,
and similar residues are highlighted in yellow. The human MSI2 RRM1 and RRM2 domains are indicated by the red and black lines, respectively
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1-328) shares a high degree of similarity to the Musashi family pro-
teins. Overall, MSI2 (residues 1-328) is 69% identical to human
Musashi-1 (MSI1; residues 1-362) and mouse MSI1 (residues
1-362). The highest degree of similarity was observed for the
N-terminal RRMs of human MSI2 (residues 21-187) which are
87% and 86% identical to the RNA-binding domains (RBDs) (resi-
dues 20-186) of human MSI1 and mouse MSI1, respectively. A mul-
tiple sequence alignment of human MSI2, human MSI1, and mouse
MSI1 using Clustal Omega24 is shown in Figure 1. The C-terminal
region of MSI2 has no known motifs or specific function, while the
N-terminal RRMs mediate the binding to mRNAs,25 including those
involved in the proliferation of certain cancers. As such, targeting
these interactions using structure-based drug design methods may
provide a route for inhibitor development. To this end, we deter-
mined the crystal and solution NMR structures of MSI2-RRM1 using
a construct that was found to bind RNA. A high degree of structural
similarity was observed between the crystal and solution NMR
structures, suggesting that an orthogonal approach using both crys-
tallographic and solution NMR methods could potentially be utilized
for subsequent ligand binding studies.
2 | MATERIALS AND METHODS
2.1 | Fluorescence polarization assay
Fluorescence polarization (FP) assays and calculation for the Kd were
carried out using our previously described methods.26 Three 30 FAM-
labelled Numb RNAs that contain the Musashi recognition motif
r(UAG) were used which included 15 nt Numb RNA (Numb15:
50UAGGUAGUAGUUUUA), 8 nt Numb RNA (Numb8: 50GUAGUAGU),
and 5 nt Numb RNA (Numb5: 50GUAGU); one 30 FAM-labelled 15 nt
RNA with scrambled sequence was used as the control (control15). All
RNAs were used at 2 nM. Fluorescence measurements were taken at
room temperature using a BioTek Synergy H4 plate reader (Biotek,
Winooski, VT).
2.2 | Protein expression and purification
MSI2-RRM1 protein used in NMR study was purified as previously
described.27 MSI2-RRM1 purification for crystallization was the
same as the NMR except the last step of the protein was purified in
the buffer of 20 mM HEPES (pH 7.5), 100 mM NaCl. To remove the
His-tag of purified MSI2-RRM1 for crystallization, determination of
the digestion efficiency of the purified proteins by TEV protease was
carried out in a total volume of 50 μL containing 100 μg of protein in
assay buffer (50 mM Tris-Cl, pH 8.0, 0.5 mM EDTA, and 10 mM
β-mercaptoethanol), and various amount of TEV protease (1-50 μg).
Experiments were performed at room temperature or at 4 C for
1 to 12 hours. The reaction was quenched by mixing with 4 × SDS-
PAGE sample buffer (40% glycerol, 564 mM Tris base, 424 mM Tris-
HCl, 8% SDS, 0.4% bromophenol blue). The degree of TEV digestion
was detected by SDS-PAGE. The quantity of the digested products
was measured qualitatively by visualization on the stained gel and
compared with the control experiment that was carried out without
TEV in the reaction. For large-scale reactions, purified proteins were
mixed with TEV at the predetermined ratio, then dialyzed exten-
sively against reaction buffer (50 mM Tris-HCl, pH 8.0, 10 mM
β-mercaptoethanol, 0.5 M NaCl) and then passed through Ni
column.
2.3 | Crystallization and data collection
Purified MSI2-RRM1 (G21-K111) with the His-tag removed was con-
centrated to 10.2 mg/mL (0.96 mM) in 150 mM NaCl, 20 mM MES
pH 6.0. All crystallization experiments were setup using an NT8 drop
setting robot (Formulatrix Inc.) and UVXPO MRC (Molecular Dimen-
sions) sitting drop vapor diffusion plates at 18C. 100 nL of protein
and 100 nL crystallization solution were dispensed and equilibrated
against 50 uL of the latter. Needle clusters (Figure S1) formed after
2 days and grew to their maximum size in 3 weeks from the Salt Rx
screen (Hampton Research) condition E4 (2.4 M [NH4]2HPO4,
100 mM Tris pH 8.5). A cryoprotectant containing 80% crystallant
and 20% (v/v) glycerol was layered onto the drop (2 uL), crystals were
harvested and stored in liquid nitrogen. X-ray diffraction data were
collected at the Advanced Photon Source beamline 17-ID using a
Dectris Pilatus 6 M pixel array detector.
2.4 | Crystal structure solution and refinement
Intensities were integrated using XDS28,29 via XDSAPP30 and the
Laue class analysis and data scaling were performed with Aimless31
which suggested that the highest probability Laue class was 2/m and
space group P2 or P21. The Matthews coefficient
32 indicated that the
asymmetric unit most likely contained a single molecule with
(Vm = 3.3 Å3/Da, 62% solvent). Structure solution was conducted by
molecular replacement with Phaser33 using a single chain from the
solution NMR structure of MSI2-RRM1 (PDB 6C8U) as the search
model. The search model included G21-V95 as the N- and C-termini
regions were highly flexible. Initial molecular replacement searches for
a single molecule in the asymmetric unit yielded a log likelihood gain
(LLG) of 18 and translation function Z-score (TFZ) of 3 suggesting that
a solution was not obtained. Although the Matthews coefficient indi-
cated that the crystals most likely contained a single molecule in the
asymmetric unit, the possibility of two molecules was also probable
(2%) with Vm = 1.6 and 25% solvent. Molecular replacement search
for two molecules yielded an LLG and TFZ of 42 and 5.6, respectively,
indicating that an improved solution was obtained but was still weak.
However, the resulting electron density maps following refinement of
this solution were interpretable. The model was subjected to iterative
rounds of manual model building and refinement, which further
improved the electron density maps. A single subunit was then used
for molecular replacement with Phaser and yielded a solution
(LLG = 680, TFZ = 16) with two molecules in the asymmetric unit in
the space group P21. Further refinement and manual model building
were conducted with Phenix34 and Coot,35 respectively. Disordered
side chains were truncated to the point for which electron density
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could be observed. Structure validation was conducted with
Molprobity,36 and figures were prepared using the CCP4MG pack-
age.37 Polder38 omit maps (Fo-Fc) were calculated with Phenix, and
structure superposition was carried out using GESAMT.39 Crystallo-
graphic data for MSI2-RRM1 are provided in Table 1. Coordinates and
structure factors were deposited to the Worldwide Protein Databank
(wwPDB) with the accession code 6NTY.
2.5 | NMR spectroscopy and structure calculation
All NMR spectra for structure calculation were recorded at 25C on a
Bruker AVANCE 800 MHz NMR spectrometer equipped with a triple
resonance cryoprobe. The NMR samples contained 400 μM-1 mM of
13C and 15N labeled MSI2-RRM1 in 20 mM MES (pH 6.0), 150 mM
NaCl. Backbone resonance assignments of MSI2-RRM1 were reported
previously under BMRB code 27111.27 Side chain assignments were
made by analyzing HCCH-COSY40 and HCCH-TOCSY41 (10.9 ms mixing
time) spectra. Distance restraints were obtained using 3D 15N edited
NOESY-HSQC42 (120 ms mixing time) and 13C edited NOESY-HSQC42
(120 ms mixing time) spectra. Spectra were processed by NMRPipe43
and analyzed by NMRViewJ.44 The15N{1H} heteronuclear nuclear Over-
hauser effect (HetNOE) spectrum was collected at 25C on a Bruker
AVIII 600 MHz NMR spectrometer equipped with a room temperature
triple resonance inverse probe. The NMR sample contained 132 μM of
15N labeled MSI2-RRM1 in 20 mM MES (pH 6.0), 150 mM NaCl. Data
were processed using nmrPipe and visualized using nmrDraw and CCPN
Analysis45 on the NMRBox46 platform. The reference and NOE experi-
ments were collected in an interleaved manner. Each 2D was collected
with 1024 × 128 complex data points with 64 scans. The interscan delay
is set to 8 seconds for the reference experiment and 5 seconds for the
NOE experiment. The NOE experiment used a train of 120 hard pulses
with 18 ms delays for a total saturation time of 3 seconds.





a = 30.80, b = 57.37,
c = 41.31, β = 101.3
Space group P21
Resolution (Å)a 40.51-2.10 (2.16-2.10)
Wavelength (Å) 1.0000
Temperature (K) 100
Observed reflections 27 686
Unique reflections 8271
<I/σ(I) >a 6.5 (1.8)
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aValues in parenthesis are for the highest resolution shell.
bRmerge = ΣhklΣi |Ii(hkl)- < I(hkl) > |/ΣhklΣi Ii(hkl), where Ii(hkl) is the intensity
measured for the ith reflection and < I(hkl) > is the average intensity of all
reflections with indices hkl.
cRfactor = Σhkl ||Fobs (hkl)|-|Fcalc (hkl)||/Σhkl|Fobs(hkl)|; Rfree is calculated in an
identical manner using 5% of randomly selected reflections that were not
included in the refinement.




eCC1/2 is the correlation coefficient of the mean intensities between two
random half-sets of data64,65.
F IGURE 2 MSI2-RRM1 binds to Numb RNA. Binding between
RNA recognition Motif 1 (aa 21-111) of MSI2 (MSI2-RRM1) to three
Numb RNAs (2 nM), but not to a Control RNA (2 nM) in FP assay
[Color figure can be viewed at wileyonlinelibrary.com]
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Structure calculation was performed using Crystallography and
NMR system (CNS)47 version 1.3. The CNS calculation used default
parameters with modifications in the high temperature annealing
stage (15 000 K), the second Cartesian cooling stage (10 000 K,
12 000 steps), the NOE energy term scale factor (200), the dihedral
angle energy term scale factor (250), and time step (0.0028). A total of
100 structures were calculated, and the 10 structures with lowest
energy were selected and superimposed. The qualities of the 10 struc-
tures were assessed by CNS and the Protein Data Bank (PDB) valida-
tion server. The ensemble of the 10 lowest energy structures and
experimental restraints in CNS format were deposited to the PDB
(PDB accession code 6C8U), and the complete resonance assignments
F IGURE 3 Crystal structure of the MSI2-RRM1 subunit. A,
Secondary structure elements for subunit A. B, Annotation of the
secondary structure elements relative to the amino acid sequence.
Residues in italics at the N-terminus are cloning artifacts, and
underlined residues were not modeled due to disorder
F IGURE 4 Crystal structure of MSI2-RRM1. A)
Noncrystallographic dimer with subunits A and B colored magenta
and green, respectively. B) Hydrogen bond interactions (dashed lines)
between the noncrystallographic dimers in the asymmetric unit. C)
Superposition of subunit B (green) onto subunit A (magenta)





NOE's sequential (|i-j| = 1) 319
NOE's medium rang (2 ≤ |i-j| ≤ 5) 178
NOE's long range (|i-j|˃5) 183
Dihedral angle restraints 148
Carbon shift restraints 108
Nonglycine Hα shifts restraints 100
Hydrogen bond restraints 38
Structure results
No. of NOE violations >0.5 Å 0
NOE violation RMSD 0.069 ± 0.000 Å
No. of phi or psi violations >5 0
phi or psi violation RMSD 0.44 ± 0.02
Hɑ shifts violation RMSDa 0.31 ± 0.01 ppm
Cɑ shifts violation RMSDa 1.24 ± 0.03 ppm
Cβ shifts violation RMSDa 0.90 ± 0.04 ppm
Bond lengths RMSDb 0.0077 ± 0.0001 Å
Bond angles RMSDb 0.77 ± 0.01
Improper angles RMSDb 0.53 ± 0.01
CNS total energy 2532 ± 7 kcal
CNS NOE energy 433 ± 5 kcal
CNS phi/psi energy 3.6 ± 0.3 kcal




Backbone atoms RMSDc 0.333 ± 0.064 Å
Heavy atoms RMSDc 0.712 ± 0.086 Å
PDB code 6C8U
aDeviations from the standard chemical shifts ranges in the CNS
databases.
bDeviations from the standard geometry used in CNS.
cIll-defined regions at residues -3-20 and 97-111 are excluded.
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of MSI2-RRM1 were deposited to the Biological Magnetic Resonance
Data Bank (BMRB accession code 30398).
3 | RESULTS AND DISCUSSION
3.1 | MSI2-RRM1 binds to Numb RNA
The N-terminal RRMs (RNA-recognition Motifs) of MSI2 mediate the
binding to their target mRNAs' recognition motifs located at 30-UTR
and one of the motifs, r(UAG), is shared between MSI1 and MSI2.48,49
FP experiments demonstrated that all three Numb RNAs containing
the Musashi recognition motif r(UAG) bind to MSI2-RRM1, as indi-
cated by the increased FP value, and MSI2-RRM1 has a higher affinity
towards Numb15 compared to Numb8 or Numb5, as indicated by the
lower Kd value (Figure 2). Importantly, compared to Numb15, the
15 nt control RNA (Control15) containing a scrambled sequence dis-
played nonspecific binding at high protein concentration (Figure 2).
Importantly, these results indicate that the MSI2-RRM1 construct
adopts a functional RNA-binding conformation in solution.
3.2 | Crystal structure of MSI2-RRM1
The crystal structure of MSI2-RRM1 was modeled from residues
G21 to R100 and consists of an antiparallel β-strand core that is
flanked by two α-helices (Figure 3). The two subunits in the asym-
metric unit form a noncrystallographic dimer in which the longest
β-stands (1, 2, 3, and 6) are positioned towards the center of the
dimer (Figure 4A). The only hydrogen bond interactions between
dimer subunits occurs between residues F97/R99 in the C-terminal
β7 strand of subunit A and residues V52, M53, and R54 in β2 of
F IGURE 5 NMR solution structure of
MSI2-RRM1 with residues -3-20 and
98-111 excluded. A, Superposition of the
backbone atoms for the 10 lowest energy
structures of MSI2-RRM1. The flexible
loop between β2-β3 is indicated by the
asterisk. B, Ribbon diagram
representation of the lowest energy
structure of MSI2-RRM1
F IGURE 6 15N{1H} HetNOE
values versus residue number of
MSI2-RRM1. Values marked with
an asterisk are not reliable due to
issues with volume measurement
in either the reference or NOE
spectrum. Red dashed line
indicates the average HetNOE
value (0.68) for residues
K22-R100. Values marked with
an arrow are greater than or
equal to one SD smaller than the
average value for the folded core.
These residues have greater
flexibility than the rest of the
protein, neglecting the N- and C-
terminal tails [Color figure can be
viewed at wileyonlinelibrary.com]
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subunit B (Figure 4B). The structures of subunits A and B are quite
similar with a root-mean-square-deviation (RMSD) of 0.81 Å (80 res-
idues aligned) between Cα-atoms. A small difference between the
subunits was in the loop that bridges β2 and β3 (Figure 4C). It
should be noted, however, that the crystals are tightly packed as
indicated by the Matthew's coefficient (Vm = 1.7 Å3/Da, 25% sol-
vent). As such, it is possible that crystal packing could affect the
conformation of the β2/β3 loop in each subunit differently. Nota-
bly, R60 in subunit A forms a contact with Q81 of a symmetry-
related molecule. However, no crystal contacts are observed with
residues in the β2/β3 loop of subunit B and residues T57 and T58
were disordered.
During the review of this manuscript, a crystal structure of a
MSI2-RRM150 construct spanning K22-K104 was released. The struc-
ture is similar overall to the structure reported here and superposition
of the new release and our structure yielded an RMSD of 1.11 Å
between Cα atoms (78 residues). The main differences were observed
in the extreme C-terminus along with slight conformational differ-
ences in the β2/β3 loop (Figure S2).
3.3 | NMR structure of MSI2-RRM1
A total of 100 structures of MSI2-RRM1 were calculated using 1183
NOE distance restraints, 148 torsion angle restraints, 108 carbon chem-
ical shift restraints, 100 nonglycine Hα chemical shift restraints, and
38 hydrogen bond restraints (Table 2). The superposition of the back-
bone atoms for the 10 lowest energy structures of MSI2-RRM1 and
ribbon diagram representation of the lowest energy structure of
MSI2-RRM1 are shown in Figure 5A,B and the statistical results of the
10 lowest energy structures are provided in Table 2. The hexahistidine
tag and TEV protease cleavage site (residues M-3-A20) and the C-
terminus (residues P98-K111) are not shown as they are unstructured.
The well-defined regions include residues G21-F97, and the ill-defined
regions include residues M-3-A20 at the N-terminus and residues
P98-K111 at the C-terminus due to the lack of inter-residue NOE's.
The RMSD of the backbone atoms is 0.333 ± 0.064 Å, and the RMSD
of the heavy atoms is 0.712 ± 0.086 Å. Based on Ramachandran analy-
sis of the structural model, 98.0% of the backbone torsion angles are in
the most favored conformational region, 2.0% are in the allowed region,
and 0% are in disallowed regions. Similar to the crystal structure of
MSI2-RRM1, the solution NMR structure of MSI2-RRM1 exhibits a
typical ribonucleoprotein (RNP)-type fold consisting of antiparallel
β-sheets (β1-β6) packed against two α-helices (α1 and α2).
3.4 | 15N{1H} HetNOE measurement
The 15N{1H} HetNOE measured at 600 MHz for MSI2-RRM1 is
reported in Figure 6. The average HetNOE value for the folded core
of MSI2-RRM1 (residues K22-R100) equals 0.68. HetNOE values that
are one SD below the average, indicative of protein regions with fast
motion on the ps-ns timescale, were detected mostly for the N-termi-
nus, residue S33 at β1-α1 loop, K59, R60, S61 at β2-β3 loop, G63 at
the beginning of β3, A70 at β3-α2 loop, D92 at the beginning of β6,
and the C-terminal end. Overall, the HetNOE data demonstrate that
the loop between β2 and β3 has greater flexibility than the rest of the
protein (excluding the N- and C-terminal tails) and that the loop con-
necting β1 and α1 is also flexible.
3.5 | MSI2-RRM1 crystal and NMR structure
comparison
The crystal structure shares a high degree of similarity with the solu-
tion NMR structure of MSI2-RRM1. Superposition of the NMR
F IGURE 7 Comparison of the MSI2-RRM1 crystal (magenta) and
solution NMR (cyan) structures. A, Superposition of the NMR
structure onto subunit A of the crystal structure. B, Zoomed-in view
of the conformational differences in the loop spanning β2-β3
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structure (model 1) onto subunit A yielded an RMSD of 1.35 Å (68 res-
idues aligned) between Cα-atoms (Figure 7A). Apart from the C-
terminal “tail” spanning residues A101-K111, which could not be
modeled in the crystal structure, the main difference was observed in
the loop that spans β2 and β3 (Figure 7B) which is shifted approxi-
mately 8.8 Å. Additionally, the backbone HetNOE data (Figure 6)
show that the β2-β3 loop has greater flexibility than the rest of the
protein, excluding the N- and C-terminal tails. As noted above, the
crystals of MSI2-RRM1 are tightly packed. As such, it is possible that
the symmetry-related molecules near the β2/β3 loop could prevent
this region from adopting the conformation observed in the NMR
structure.
3.6 | MSI2-RRM1 comparison with MSI1-RBD1 and
other RBPs
The crystal structure was compared with solution NMR structures of
the apo and RNA bound forms of the MSI1-RBD1 homolog from
M. musculus. Superposition of apo (1UAW) and RNA bound (2RS2)
MSI1-RBD1 onto chain A of the MSI2-RRM1 crystal structure yielded
RMSD of 2.17 Å (73 residues) and 0.82 Å (71 residues), respectively
(Figure S3). Although the apo MSI1-RBD1 structure displayed a higher
RMSD, the overall structure is quite similar. The main differences arise
in the loops connecting the helical and sheet secondary structure
elements.
Evidence presented above suggests that the loop connected β2
and β3 displays a high degree of flexibility. Comparing this region of
the MSI2-RRM1 crystal structure with the lowest energy conforma-
tion of the RNA bound form of MSI1-RBD1, revealed that this loop
clashes with RNA and would need to undergo a conformational
change to accommodate binding (Figure 8A). Interestingly, the
MSI2-RRM1 solution NMR structure appears to adopt a conformation
similar to the RNA bound form in this region (Figure 8B). This is fur-
ther supported by comparison with the lowest energy conformation
of the apo structure of MSI1-RBD1. As shown in Figure 8C,D, the β2/
β3 loop in crystal structure of MSI2-RRM1 adopts a similar conforma-
tion observed for the apo MSI1-RBD1 structure.
The MSI2-RRM1 solution NMR structure ensembles were also
compared with the MSI1-RBD1 ensembles. Superposition of apo
(1UAW) and RNA bound (2RS2) MSI1-RBD1 onto chain A of the
MSI2-RRM1 solution NMR structure yielded RMSD of 1.77 Å (69 resi-
dues) and 1.26 Å (77 residues), respectively. Interestingly, the NMR
model ensembles for MSI2-RRM1 and RNA bound MSI1-RBD1 show
only minor conformational differences (Figure S4A). However, the
superimposed ensembles of apo MSI1-RBD1 displayed a high degree
of difference in the β2/β3 loop (Figure S4B). The apo MSI1-RBD1
structure adopts a wide conformational range in this loop spanning
approximately 14 Å. In the RNA bound MSI1-RBD1 structure, Arg
61 was shown to form an electrostatic interaction with an RNA phos-
phate group which likely serves to stabilize the β2/β3 loop. This
F IGURE 8 Comparison of the
MSI2-RRM1 crystal (magenta) and
solution NMR (cyan) structures with
RNA bound MSI1-RBD1 (2RS2, gold)
and apo MSI1-RBD1 (1UAW, green).
The RNA from 2RS2 is rendered as
cylinders. The loop connecting β2-β3 is
highlighted in each panel. A,
MSI2-RRM1 crystal structure with
2RS2. B, MSI2-RRM1 NMR structure
with 2RS2. C, MSI2-RRM1 crystal
structure with 1UAW. D, MSI2-RRM1
NMR structure with 1UAW
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corresponding residue in MSI2-RRM1 (Arg 62) adopts a similar con-
formation in the solution NMR structure but occupies the RNA bind-
ing cleft in the crystal structure (Figure 9A).
Although it is unclear why the β2/β3 loop adopts the RNA bound
conformation in the solution NMR structure of MSI2-RRM1, this fea-
ture is not unique to MSI2-RRM1. The NMR structure of MSI2-RRM1
displayed a high degree of similarity in the β2/β3 loop to many other
apo RRMs. For example, the NMR structure of HNRNP A1 RRM1
(PDB ID: 2LYV51; RMSD for 70 Cα-atoms: 1.16 Å), the crystal struc-
ture of HNRNP A1 RRM1(PDB ID: 1UP152; RMSD for 73 Cα-atoms:
1.11 Å), the NMR structure of CYP33 RRM (PDB ID: 2KYX53; RMSD
for 61 Cα-atoms: 1.16 Å), the NMR structure of Hu antigen C RBD1
(PDB ID: 1D8Z54; RMSD for 61 Cα-atoms: 1.47 Å), the crystal struc-
ture of hnRNP A18 RRM (PDB ID: 5TBX55; RMSD for 66 Cα-atoms:
1.39 Å), and the NMR structure of drosophila sex-lethal RBD1 (PDB
ID: 2SXL56; RMSD for 61 Cα-atoms: 1.61 Å). Interestingly, the NMR
structures of both apo and RNA bound form of HNRNP A1 RRM1
(PDB ID 2LYV and 5MPG57) are similar to the NMR structure of
MSI2-RRM1 in that the β2/β3 loop and Arg 55 (corresponding to Arg
62 in MSI2-RRM1) of the apo HNRNP A1 RRM1 adopts the RNA
bound conformation (Figure 9B).
The NMR and crystal structures of MSI2-RRM1 are similar to other
RBPs as they all adopt a canonical RNP type folding: a β1α1β2β3α2β4
topology that forms a four-stranded β-sheet packed against two
α-helices and utilize two highly conserved regions, RNP1 and RNP2, to
bind to RNA. RNP1 is located on β3 and is defined as Lys/Arg-Gly-Phe/
Tyr-Gly/Ala-Phe/Tyr-Val/Ile/Leu-X-Phe/Tyr, where X can be any
amino acid.58,59 RNP2 is located on β1 and is defined as (Ile/Val/Leu)-
(Phe/Tyr)-(Ile/Val/Leu)-X-Asn-Leu.60 The aromatic base stacking inter-
action between the aromatic residues in RNP1 and RNP2 and the RNA
bases are a common feature in RBP/RNA complexes. Based on our pre-
viously published RNA titration work, in MSI2-RRM1, F64 and F66 in
RNP1 and F24 in RNP2 are likely to be responsible for the canonical
aromatic base stacking interaction with RNA. Compared with other
RBPs, MSI2-RRM1 has a potentially unique feature in that a tryptophan
in the β1-ɑ1 loop (W30) and a phenylalanine in the C-terminus (F97)
may form noncanonical base-stacking interactions with RNA.27 So far,
we find that this feature is likely limited to the Musashi family proteins.
4 | CONCLUSION
Here, we obtained the crystal and NMR structures of MSI2-RRM1
and compared the structures to that of MSI1-RBD1 and other RBPs.
We showed that MSI2-RRM1 adopts a canonical RNP type folding
that is similar to other RBPs. The chemical shift assignments and
structural information of MSI2-RRM1 will be helpful for understand-
ing MSI2-RNA interaction and guiding rational drug design of
MSI2-specific inhibitors because MSI2-RRM1 is the key motif that is
responsible for the binding of MSI2 to its target mRNAs.
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